Sodium Bicarbonate Tablet
NDC Package 70369-002-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Sodium Bicarbonate tablets is do not use the maximum dosage for more than 2 weekstablets may be swallowed whole or dissolved in water prior to useadults 60 years of age and over: 2-4 tablets every 4 hours, not more than 24 tablets in 24 hours adults under 60 years of age: 2-8 tablets every 4 hours, not more than 48 tablets in 24 hours. This formulation utilizes a tablet delivery system. Marketed by Citragen Pharmaceuticals Inc., this product is identified by NDC 70369-002 and is authorized under FDA application M001.

Identification & Billing

NDC Package Code
70369-002-01
Package Description
1000 TABLET in 1 BOTTLE
Product Code
70369-002
11-Digit Billing Format
70369000201
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1000 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Sodium Bicarbonate 5 Gr (325 Mg)
Non-Proprietary Name
Sodium Bicarbonate
Substance Name
Sodium Bicarbonate
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
SODIUM BICARBONATE 325 mg/1
Pharmacologic Class
Usage Information
Do not use the maximum dosage for more than 2 weekstablets may be swallowed whole or dissolved in water prior to useadults 60 years of age and over: 2-4 tablets every 4 hours, not more than 24 tablets in 24 hours adults under 60 years of age: 2-8 tablets every 4 hours, not more than 48 tablets in 24 hours

Regulatory & Marketing

Labeler Name
Citragen Pharmaceuticals Inc.
Product Type
Human Otc Drug
FDA Application #
M001
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
04-20-2018
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70369-002-01 identifies a specific commercial package of 1000 tablet in 1 bottle of Sodium Bicarbonate 5 Gr (325 Mg), a human over the counter drug labeled by Citragen Pharmaceuticals Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1000 billable units per package. This tablet is formulated for oral use and contains sodium bicarbonate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Citragen Pharmaceuticals Inc. on April 20, 2018. The current certification is valid through December 31, 2026.

How is this Citragen Pharmaceuticals Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70369000201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1000 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70369-002-01
11-Digit CMS (5-4-2)
70369-0002-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.